NeuproGemp, a polyphenol-rich botanical formula, ameliorates Alzheimer’s-like pathology in APP/PS1 mice via inhibition of human glutaminyl cyclase
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and amyloid-β (Aβ) accumulation. Increasing evidence suggests that dietary bioactive compounds may modulate neurodegenerative processes. Here, we evaluated the neuroprotective potential of NeuproGemp, a traditional Chinese functional food formula composed of <i>Gastrodia elata</i>, <i>Paeoniae Radix Rubra</i>, and the immunomodulatory protein GMI from <i>Ganoderma microsporum</i>, in APP/PS1 transgenic mice. Oral supplementation (300 mg/kg/day, 6-8 weeks) significantly improved ethological behaviors, including a ∼150% enhancement in burrowing performance (150 ± 25 g vs. 60 ± 40 g in controls), and reduced escape latency in the Morris water maze (Day 4: p < 0.05; Day 6: p < 0.01). Histological analyses demonstrated attenuated plaque-associated gliosis, with microglial/astroglial clusters reduced from 95 ± 22 to 55 ± 11 per section (p < 0.01), alongside increased hippocampal neurogenesis (DCX + cells: 49 vs. 18 cells/mm, p < 0.001). ELISA revealed reductions of ∼30% in soluble Aβ<sub>1-42</sub> and ∼50% in pyroglutamate-modified Aβ<sub>3-42</sub> (pE-Aβ<sub>3-42</sub>). High-performance liquid chromatography identified pentagalloylglucose (PGG) as the principal polyphenolic constituent of <i>Paeoniae Radix Rubra</i>, which exhibited potent human glutaminyl cyclase (hQC) inhibition (IC<sub>50</sub> = 0.09 μM; KD = 63.7 nM). Molecular modeling and dynamics simulations further supported stable binding interactions of PGG and tannic acid with hQC. Collectively, these findings indicate that NeuproGemp, enriched in neuroactive polyphenols, exerts multi-targeted modulation of amyloidogenic pathways and represents a promising botanical intervention for mitigating AD-related neuropathology.
Authors
- Wang-Chuan Chen
- Young‐Ji Shiao (ORCID: https://orcid.org/0000-0002-2699-116X)
- Keng‐Chang Tsai (ORCID: https://orcid.org/0000-0001-8277-9174)
- Tien‐Sheng Tseng (ORCID: https://orcid.org/0000-0003-0515-1855)
- Chia‐Ching Liaw (ORCID: https://orcid.org/0000-0001-5642-4679)
- Yu-Hsiu Cheng (ORCID: https://orcid.org/0000-0001-6892-6529)
- Ya-I Huang
Institutions
- National Chung Hsing University (TW)
- Genomics Research Center, Academia Sinica (TW)
- E-Da Hospital (TW)
- National Research Institute of Chinese Medicine (TW)
- Ministry of Health and Welfare (TW)
- GenMont Biotech (Taiwan) (TW)
- Taipei Medical University (TW)
- National Yang Ming Chiao Tung University (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fphar.2025.1673532
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science and Technology Council